Shanghai Haohai Biological Technology Future Growth
Future criteria checks 3/6
Shanghai Haohai Biological Technology is forecast to grow earnings and revenue by 16.8% and 11.8% per annum respectively. EPS is expected to grow by 25.4% per annum. Return on equity is forecast to be 9.7% in 3 years.
Key information
16.8%
Earnings growth rate
25.4%
EPS growth rate
| Biotechs earnings growth | 42.8% |
| Revenue growth rate | 11.8% |
| Future return on equity | 9.7% |
| Analyst coverage | Low |
| Last updated | 13 Nov 2024 |
Recent future growth updates
Recent updates
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease
Jul 25
Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All
May 22Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Apr 17Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?
Feb 12Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Nov 14Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 28We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Mar 09These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Nov 25Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 30Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price
May 08Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Apr 19Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
Mar 04Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 03Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?
Jan 10Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Oct 08Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly
Jul 07Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%
May 27These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Apr 04Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%
Mar 16Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3,517 | 638 | N/A | N/A | 1 |
| 12/31/2025 | 3,153 | 565 | N/A | N/A | 1 |
| 12/31/2024 | 2,751 | 478 | N/A | N/A | 1 |
| 9/30/2024 | 2,747 | 430 | 325 | 674 | N/A |
| 6/30/2024 | 2,746 | 446 | 296 | 679 | N/A |
| 3/31/2024 | 2,689 | 432 | 239 | 630 | N/A |
| 12/31/2023 | 2,654 | 416 | 367 | 634 | N/A |
| 9/30/2023 | 2,530 | 346 | 99 | 442 | N/A |
| 6/30/2023 | 2,487 | 315 | 92 | 401 | N/A |
| 3/31/2023 | 2,263 | 226 | -35 | 254 | N/A |
| 12/31/2022 | 2,130 | 180 | -86 | 231 | N/A |
| 9/30/2022 | 2,063 | 203 | 52 | 343 | N/A |
| 6/30/2022 | 1,861 | 192 | 57 | 336 | N/A |
| 3/31/2022 | 1,805 | 272 | 64 | 339 | N/A |
| 12/31/2021 | 1,750 | 352 | 70 | 342 | N/A |
| 9/30/2021 | 1,702 | 428 | 115 | 333 | N/A |
| 6/30/2021 | 1,674 | 434 | 120 | 342 | N/A |
| 3/31/2021 | 1,594 | 370 | N/A | N/A | N/A |
| 12/31/2020 | 1,324 | 230 | 66 | 262 | N/A |
| 9/30/2020 | 1,343 | 232 | -20 | 258 | N/A |
| 6/30/2020 | 1,306 | 216 | 6 | 258 | N/A |
| 3/31/2020 | 1,437 | 279 | N/A | N/A | N/A |
| 12/31/2019 | 1,595 | 371 | -50 | 349 | N/A |
| 9/30/2019 | 1,537 | 353 | -8 | 286 | N/A |
| 6/30/2019 | 1,570 | 386 | -7 | 302 | N/A |
| 3/31/2019 | 1,478 | 375 | N/A | N/A | N/A |
| 12/31/2018 | 1,546 | 415 | 239 | 391 | N/A |
| 9/30/2018 | 1,523 | 411 | 235 | 398 | N/A |
| 6/30/2018 | 1,501 | 408 | N/A | 404 | N/A |
| 3/31/2018 | 1,423 | 390 | N/A | 374 | N/A |
| 12/31/2017 | 1,345 | 372 | N/A | 343 | N/A |
| 9/30/2017 | 1,214 | 351 | N/A | 330 | N/A |
| 6/30/2017 | 1,083 | 329 | N/A | 317 | N/A |
| 3/31/2017 | 967 | 317 | N/A | 286 | N/A |
| 12/31/2016 | 851 | 305 | N/A | 254 | N/A |
| 9/30/2016 | 787 | 295 | N/A | 245 | N/A |
| 6/30/2016 | 724 | 284 | N/A | 235 | N/A |
| 3/31/2016 | 694 | 279 | N/A | 252 | N/A |
| 12/31/2015 | 664 | 273 | N/A | 269 | N/A |
| 9/30/2015 | 630 | 258 | N/A | 244 | N/A |
| 6/30/2015 | 597 | 243 | N/A | 219 | N/A |
| 3/31/2015 | 556 | 213 | N/A | 181 | N/A |
| 12/31/2014 | 516 | 184 | N/A | 142 | N/A |
| 9/30/2014 | 482 | 169 | N/A | 135 | N/A |
| 6/30/2014 | 449 | 154 | N/A | 128 | N/A |
| 3/31/2014 | 425 | 148 | N/A | 137 | N/A |
| 12/31/2013 | 401 | 142 | N/A | 147 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6826's forecast earnings growth (16.8% per year) is above the savings rate (2.3%).
Earnings vs Market: 6826's earnings (16.8% per year) are forecast to grow faster than the Hong Kong market (11.4% per year).
High Growth Earnings: 6826's earnings are forecast to grow, but not significantly.
Revenue vs Market: 6826's revenue (11.8% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 6826's revenue (11.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6826's Return on Equity is forecast to be low in 3 years time (9.7%).